Carmen Rodríguez-Cerdeira, MD; Elena Sánchez-Blanco

Dr. Rodríguez-Cerdeira is from the Dermatology Department, CHUVI and University of Vigo, Vigo, Spain; Sánchez-Blanco is a Postgraduate researcher, University of Vigo, Vigo, Spain Read the rest of this article »

Moetaz El-Domyati, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt; Tarek S. El-Ammawi, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt; Walid Medhat, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania; Osama Moawad, MD, Moawad Skin Institute for Laser, Cairo, Egypt; My G. Mahoney, PhD, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania; Jouni Uitto, MD, PhD, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania Read the rest of this article »

Douglas Mest, MD; Gail Humble, MD, Blue Pacific Aesthetic Medical Group, Hermosa Beach, California

Abstract
Injectable poly-L-lactic acid is United States Food and Drug Administration–approved for the restoration and/or correction of the signs of lipoatrophy in people with human immunodeficiency virus and for use in immune-competent people for the correction of nasolabial fold contour deficiencies. Current prescribing information recommends using either a tunneling or threading technique in a grid or cross-hatched pattern or a depot technique (in thin skin areas) to administer multiple passes of injectable poly-L-lactic acid per treatment session via a 26-gauge needle. A review of the literature and the recently published guidelines from the American Society for Dermatologic Surgery provide evidence to support the use of a cross-fanning technique with a 25-gauge needle. In conclusion, the use of a cross-fanning injection technique with a 25-gauge needle to administer injectable poly-L-lactic acid provides a clinically valid, alternate delivery option for the treatment of patients with human immunodeficiency virus-associated lipoatrophy.
(J Clin Aesthet Dermatol. 2010;3(12):43–49.) Read the rest of this article »

George Martin, MD
Dermatology and Laser Center of Maui, Kihei, Hawaii Read the rest of this article »

Joseph Bikowski, MD
Clinical Assistant Professor, Department of Dermatology, Ohio State University, Columbus, Ohio; Bikowski Skin Care Center at Sewickley Station, Sewickley, Pennsylvania

Dr. Bikowski discloses the following: Allergan—speakers’ bureau, honoraria; Coria—advisory board, consultant, honoraria, speakers’ bureau; Galderma—advisory board, consultant, honoraria, speakers’ bureau; OrthoNeutrogena—advisory board, consultant, honoraria, speakers’ bureau; Stiefel, a GSK Company—advisory board, consultant, honoraria, speakers’ bureau. Read the rest of this article »

Joel Schlessinger, MD, FAAD, FAACS; Daniel Schlessinger; Bernard Schlessinger, PhD
Advanced Skin Research Center, Omaha, Nebraska

Disclosure: Dr. Joel Schlessinger is a researcher for Medicis, Allergan, Merz, and Mentor. Daniel Schlessinger and Dr. Bernard Schlessinger report no relevant conflicts of interest. Read the rest of this article »

M.T. Ravi Subbiah, PhD

Dr. Subbiah is from the Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio. Disclosure: Dr. Subbiah reports no relevant conflicts of interest.

Abstract
Nutrigenomics is a growing field related to genetic testing based on the documentation of genetic mutations in an individual, giving us the ability to correct metabolic imbalances (personalized medicine) through specific dietary supplements or nutraceuticals. An off-shoot of nutrigenomics called dermagenetics (testing for selected genetic mutations related to skin health followed by advocating the use of either nutraceuticals or skin creams enriched by cosmeceuticals) is heading toward commercialization at a rapid rate by directly targeting the public. Although this growth represents an opportunity to explore the benefits of genetic advances in skin health, it is essential that the science, product claims, and ethical standards be critically evaluated and clear national guidelines be set in order to protect the consumer. Read the rest of this article »

Shannon M. Campbell, DO, Ohio University College of Osteopathic Medicine, Department of Specialty Medicine, O’Bleness Memorial Hospital, Athens, Ohio; Sara B. Peters, MD, The Ohio State University, Division of Dermatopathology, Columbus, Ohio; Matthew J. Zirwas, MD, The Ohio State University, Division of Dermatology, Columbus, Ohio; Henry K. Wong, MD, The Ohio State University, Division of Dermatology, Columbus, Ohio

Disclosure: Drs. Campbell, Peters, and Zirwas have no conflict of interests to declare. Dr. Wong has served as an advisor for EISAI.

Abstract
The application of CD markers to medicine has advanced our understanding of several dermatological diseases, most notably primary cutaneous lymphomas. CD markers are monoclonal antibodies that target cell surface molecules on leukocytes and antigens from other cells. T-cell processes are typically CD3+, CD20-, CD45+ while B-cell processes are typically CD3-, CD20+, and CD45+. Other CD markers are used to further delineate cutaneous lymphomas. Although an imperfect system, CD markers empower dermatologists to synthesize immunophenotyping with clinical findings and formulate an appropriate diagnosis.  (J Clin Aesthet Dermatol. 2010;3(10):21–25.) Read the rest of this article »

James Q. Del Rosso, DO, Dermatology Residency Director, Valley Hospital Medical Center, Las Vegas, Nevada; Radhakrishnan Pillai, PhD, Associate Director Project Management, Dow Pharmaceutical Sciences Inc., Petaluma, California; Robert Moore, PhD, Associate Principal Scientist, Dow Pharmaceutical Sciences Inc., Petaluma, California

Disclosure: Dr. Del Rosso is a consultant, speaker, and researcher for Coria/Valeant, Allergan, Galderma, Graceway, Intendis, Medicis, Onset Therapeutics, Ortho Dermatologics, Pharmaderm/Nycomed, Promius, Ranbaxy, Stiefel/GSK, Triax, Unilever, and Warner-Chilcott. Drs. Pillai and Moore are employees of Dow Pharmaceutical Sciences Inc. Read the rest of this article »

Sharon E. Jacob, MD, Univeristy of Miami, Department of Dermatology and Cutaneous Surgery, Miami, Florida, University of California, San Diego, Division of Dermatology,
San Diego, California; Aparche Yang, MD, University of California–Los Angeles, Department of Pathology and Laboratory Medicine Division of Dermatopathology; Elise Herro, MD, University of California, San Diego, Division of Dermatology, San Diego, California; Chi Zhang, PhD, University of Miami, Director of Program Evaluation, Miami, Florida; Consultant (research methodology and statistical analyses)

Disclosure: The authors report no relevant conflicts of interest. Dr. Jacob has served as an investigator for Smarthealth USA on the PREA trial investigating the efficacy and safety of the TRUE test in children. Read the rest of this article »